DK1237886T3 - Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor - Google Patents
Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptorInfo
- Publication number
- DK1237886T3 DK1237886T3 DK00983240T DK00983240T DK1237886T3 DK 1237886 T3 DK1237886 T3 DK 1237886T3 DK 00983240 T DK00983240 T DK 00983240T DK 00983240 T DK00983240 T DK 00983240T DK 1237886 T3 DK1237886 T3 DK 1237886T3
- Authority
- DK
- Denmark
- Prior art keywords
- carboxylic acid
- acid compound
- nmda receptor
- quinoline carboxylic
- compound active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9929037.1A GB9929037D0 (en) | 1999-12-08 | 1999-12-08 | Heterocyclic derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1237886T3 true DK1237886T3 (da) | 2006-08-14 |
Family
ID=10865952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00983240T DK1237886T3 (da) | 1999-12-08 | 2000-12-07 | Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor |
Country Status (30)
Country | Link |
---|---|
US (2) | US6713491B2 (cs) |
EP (1) | EP1237886B1 (cs) |
JP (1) | JP4311901B2 (cs) |
KR (1) | KR100788579B1 (cs) |
CN (1) | CN1325488C (cs) |
AR (1) | AR030923A1 (cs) |
AT (1) | ATE323691T1 (cs) |
AU (1) | AU769232B2 (cs) |
BR (1) | BR0016235A (cs) |
CA (1) | CA2393303C (cs) |
CO (1) | CO5251474A1 (cs) |
CY (1) | CY1106105T1 (cs) |
CZ (1) | CZ301052B6 (cs) |
DE (1) | DE60027461T2 (cs) |
DK (1) | DK1237886T3 (cs) |
ES (1) | ES2257343T3 (cs) |
GB (1) | GB9929037D0 (cs) |
HK (1) | HK1047436B (cs) |
HU (1) | HUP0203650A3 (cs) |
IL (2) | IL150010A0 (cs) |
MX (1) | MXPA02005802A (cs) |
MY (1) | MY129892A (cs) |
NO (1) | NO323263B1 (cs) |
PL (1) | PL356713A1 (cs) |
PT (1) | PT1237886E (cs) |
TN (1) | TNSN00240A1 (cs) |
TR (1) | TR200201503T2 (cs) |
TW (1) | TW524804B (cs) |
WO (1) | WO2001042238A1 (cs) |
ZA (1) | ZA200204492B (cs) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4616168B2 (ja) * | 2003-04-25 | 2011-01-19 | 日本ケミファ株式会社 | (2s,3s)−3−[[(1s)−1−イソブトキシメチル−3−メチルブチル]カルバモイル]オキシラン−2−カルボン酸の塩 |
GB0327912D0 (en) * | 2003-12-02 | 2004-01-07 | Glaxo Group Ltd | Medicament |
US7576216B2 (en) * | 2004-07-30 | 2009-08-18 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
PT3056492T (pt) | 2004-10-08 | 2021-12-27 | Abbvie Inc | Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) |
ME02003B (me) * | 2005-04-11 | 2012-12-31 | Abbott Lab | Farmaceutske smeše koje imaju unapređene profile rastvaranja za lekove koji su slabo rastvorljivi |
BR112014009910B1 (pt) * | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
US6413959B1 (en) * | 1995-04-14 | 2002-07-02 | Boehringer Ingelheim Kg | Method of treating depression with arylglycinamide derivatives |
WO1997012870A1 (en) * | 1995-09-29 | 1997-04-10 | Glaxo Wellcome S.P.A. | Tetrahydroquinolines as nmda antagonists |
GB9617305D0 (en) | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
-
1999
- 1999-12-08 GB GBGB9929037.1A patent/GB9929037D0/en not_active Ceased
-
2000
- 2000-07-12 US US10/148,434 patent/US6713491B2/en not_active Expired - Fee Related
- 2000-12-06 MY MYPI20005714A patent/MY129892A/en unknown
- 2000-12-07 DE DE60027461T patent/DE60027461T2/de not_active Expired - Lifetime
- 2000-12-07 AU AU20060/01A patent/AU769232B2/en not_active Ceased
- 2000-12-07 ES ES00983240T patent/ES2257343T3/es not_active Expired - Lifetime
- 2000-12-07 IL IL15001000A patent/IL150010A0/xx unknown
- 2000-12-07 PT PT00983240T patent/PT1237886E/pt unknown
- 2000-12-07 MX MXPA02005802A patent/MXPA02005802A/es active IP Right Grant
- 2000-12-07 PL PL00356713A patent/PL356713A1/xx not_active Application Discontinuation
- 2000-12-07 DK DK00983240T patent/DK1237886T3/da active
- 2000-12-07 AR ARP000106511A patent/AR030923A1/es unknown
- 2000-12-07 TR TR2002/01503T patent/TR200201503T2/xx unknown
- 2000-12-07 CO CO00093651A patent/CO5251474A1/es not_active Application Discontinuation
- 2000-12-07 CZ CZ20021981A patent/CZ301052B6/cs not_active IP Right Cessation
- 2000-12-07 JP JP2001543537A patent/JP4311901B2/ja not_active Expired - Fee Related
- 2000-12-07 CN CNB00816875XA patent/CN1325488C/zh not_active Expired - Fee Related
- 2000-12-07 KR KR1020027007260A patent/KR100788579B1/ko not_active IP Right Cessation
- 2000-12-07 TW TW089126096A patent/TW524804B/zh not_active IP Right Cessation
- 2000-12-07 EP EP00983240A patent/EP1237886B1/en not_active Expired - Lifetime
- 2000-12-07 AT AT00983240T patent/ATE323691T1/de active
- 2000-12-07 WO PCT/EP2000/012335 patent/WO2001042238A1/en active IP Right Grant
- 2000-12-07 BR BR0016235-3A patent/BR0016235A/pt not_active Application Discontinuation
- 2000-12-07 CA CA002393303A patent/CA2393303C/en not_active Expired - Fee Related
- 2000-12-07 HU HU0203650A patent/HUP0203650A3/hu unknown
- 2000-12-08 TN TNTNSN00240A patent/TNSN00240A1/en unknown
-
2002
- 2002-06-03 IL IL150010A patent/IL150010A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204492A patent/ZA200204492B/xx unknown
- 2002-06-06 NO NO20022682A patent/NO323263B1/no not_active IP Right Cessation
- 2002-12-14 HK HK02109085.5A patent/HK1047436B/zh not_active IP Right Cessation
-
2004
- 2004-02-10 US US10/775,709 patent/US6943176B2/en not_active Expired - Fee Related
-
2006
- 2006-06-26 CY CY20061100855T patent/CY1106105T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0981527T3 (da) | Salt af et naphthyridincarboxylsyrederivat | |
NO20024387L (no) | Karboksylsyrederivater som IP-antagonister | |
DK1163207T3 (da) | Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin | |
GB2357759B (en) | Iodonium salts as latent acid donors | |
DK1244647T3 (da) | Quinzolinderivater som VIGF-inhibitorer | |
NO20011349L (no) | 4-Aminosubstituerte 2-substituerte 1,2,3,4- tetrahydrokinoliner som CETP inhibitorer | |
DK0888317T3 (da) | Substituerede 4-hydroxy-phenylalkansyrederivater med agonistaktivitet over for PPAR-gamma | |
DK1009436T3 (da) | Acridinderivat til forøgelse af taxols orale biotilgængelighed | |
NO20013684D0 (no) | Substituerte fenetylaminderivater | |
DE60043730D1 (de) | Arylsulfonamid-substituierte hydroxamsäure-derivate | |
DK1328499T3 (da) | Fremgangsmåde til fremstilling af carboxylsyresalte | |
DK1237886T3 (da) | Megluminsalt af en specifik quinolincarboxylsyreforbindelse, der er aktiv på NMDA-receptor | |
DK1228073T3 (da) | Imidazolforbindelser som phosphodiesterase VII-inhibitorer | |
HRPK20040372B3 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
DK1210326T3 (da) | Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer | |
FI20000869A0 (fi) | Menetelmä kiinnirullaimen toimintavarmuuden parantamiseksi | |
NO20020774L (no) | Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse | |
WO2001070662A3 (en) | 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors | |
DK1114050T3 (da) | Fremgangsmåde til fremstilling af et naphthyridincarboxylsyrederivat (methansulfonat-sesquihydrat) | |
DE60009319D1 (de) | Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität | |
EP1043311A4 (en) | BIPHENYLAMIDINE DERIVATIVES | |
NO20002904D0 (no) | (E)-3-[1-N-butyl-5-[2-(2-karboksylfenyl)metoksy-4-klorfenyl]- 1H-pyrazol-4-yl]-2-[(5-metoksy-2,3-dihydrobenzofuran-6-yl)methyl]- prop-2-ensyre monoagrininsalt | |
IS6007A (is) | Ný morfólínóbensamíðsölt | |
FR2798134B1 (fr) | Ruban adhesif sur support non tisse dechirable a la main | |
NO20022429L (no) | Zeolitt-holdig renseblanding for tekstiler |